The effect of Adalimumab in the treatment of patients with chronic schizophrenia

Studying the effect of Adalimumab in the treatment of patients with chronic schizophrenia: A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N126

Enrollment

Registered

2020-05-17

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Subcutaneous injection of Adalimumab (40 mg) (CinnaGen, Tehran) by pen-injector at weeks 0 and 4. Intervention 2: Control group: Subcutaneous injection of normal sa

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of positive and negative symptoms based on DSM-5 Attending hospital with a psychosis attack Age between 18 to 60 years old

Exclusion criteria

Exclusion criteria: Head trauma History of shock therapy during past three months prior to the trial Undergoing neurosurgery Presence of acute or chronic systemic diseases History of allergy to the medication used in this research Receiving any anti-psychotic medications during past eight weeks prior to the trial

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026